Ozone Therapy Relieves Symptoms of Chronic Fatigue and Myalgic Encephalomyelitis
Type: Clinical trial
Author: Umberto Tirelli, Marianno Franzini, Luigi Valdenassi, Sergio Pandolfi Massimiliano Berretta Giovanni Ricevuti and Salvatore Chirumbolo
Summary:
Oxygen-Ozone Therapy May Help Reduce Fatigue in ME/CFS Patients
This study investigated the potential benefits of oxygen-ozone autohemotherapy (O2-O3-AHT) for treating fatigue in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Key Findings:
- Nearly half (43.5%) of the treated patients reported a significant improvement in fatigue, with scores on a fatigue severity scale dropping from the worst (7) to the best (1).
- Over 77% of patients experienced a notable reduction in fatigue (delta score of 4-6 points).
- No side effects were reported following O2-O3-AHT treatment.
What is O2-O3-AHT?
O2-O3-AHT is a therapy involving the withdrawal of a small amount of blood, treating it with ozone, and then reintroducing it into the bloodstream.
The research is promising, but further investigation is needed to understand the mechanisms behind these improvements.
If you are interested in learning more about O2-O3-AHT and ME/CFS, please contact us.